Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function -- PAS-003 is a monoclonal antibody targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) --   -- Lead α5/β1 integrin drug candidate to be selected in H2 2023 --  ...

Medolife Rx Launches Pharmacokinetic Study on Lead Drug Candidate as Next Step in Pre-IND FDA Submission BURBANK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product...

Medolife Rx Submits Final Data Set to FDA for IND Filing on Lead Drug Candidate BURBANK, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product...